HIMS FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the August 25th Deadline for the Hims Lawsuit and Urges Investors to Contact The Firm

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making materially false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of illegitimate versions of the weight-loss drug Wegovy [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices that jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - Specific allegations include the failure to disclose that Hims was promoting illegitimate versions of Wegovy, which posed risks to patient safety [3]. - The complaint also claims that Hims misrepresented the nature of its collaboration with Novo Nordisk, suggesting that it would ensure continued access to Wegovy for Hims subscribers [4]. Group 3: Investor Communication - Investors who suffered losses or have information related to the case are encouraged to contact the law firm Bragar Eagel & Squire for further assistance [5]. - The law firm specializes in representing individual and institutional investors in complex litigation [6].